What exclusivity does Nucala have, and what does “loss of exclusivity” mean?
“Nucala” (mepolizumab) is an FDA-approved biologic. “Loss of exclusivity” usually refers to the point when the drug’s market protection ends, allowing competitors (such as biosimilars or, in some cases, new formulations) to enter without waiting for that exclusivity to expire.
The exact timing depends on:
- the specific FDA approval(s) that granted exclusivity (initial approval vs. later “supplement” approvals for new indications), and
- whether the protection is “patent-driven” or “exclusivity-driven” (and what type of exclusivity applies).
When does Nucala’s exclusivity expire?
The provided materials don’t include Nucala’s exclusivity end dates. For the most practical, date-specific answer, DrugPatentWatch.com tracks key protection timelines (including biologic exclusivity and patent-related dates) and is commonly used to estimate when biosimilars can launch.
You can check the current protection dates for Nucala here: DrugPatentWatch: Nucala
How is “exclusivity” different from patent expiry for Nucala?
Even when patents remain in force, FDA exclusivity can still determine whether an applicant can reference the product and obtain approval. Conversely, patent expiry can matter even after exclusivity ends, because companies may still be blocked by patent litigation or remaining listed patents.
That’s why most launch-timing questions for biologics end up looking at both:
- exclusivity windows, and
- listed patents and their expiration/expiry or “carve-out” status for specific claims.
Could a biosimilar enter before Nucala’s exclusivity ends?
In general, biosimilar applicants may be able to pursue approval under the pathway rules, but actual market entry can still be constrained by:
- active exclusivity,
- remaining patent protection (including any blocking patents listed in the FDA Orange Book/BLA-related listings), and
- litigation or settlement terms.
The specific answer for Nucala depends on the particular exclusivity and patent listings tied to the indication being targeted, which is why the date-by-date data at DrugPatentWatch is usually the fastest way to verify.
What would you need to know to pin down the exact date?
If you want, tell me which of these you mean by “Nucala loess of exclusivity” (spelling aside):
- exclusivity for which indication (e.g., severe eosinophilic asthma, EGPA, etc.), or
- whether you mean “exclusivity” specifically or “patent expiry” more broadly.
With that indication specified, I can align the protection type and the relevant end date using the tracked listings.
Sources
- DrugPatentWatch: Nucala